Special Issue

State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers

Message from the Guest Editors

Drug resistance is an overwhelming challenge in cancer treatment, particularly in the context of targeted therapies. Targeted therapies are designed to inhibit specific proteins or pathways that are critical for tumour growth and progression. Genetic alterations, bypass signalling, altered drug transport/metabolism, epigenetic changes, tumour heterogeneity, the tumour microenvironment, and adaptive evolution all contribute to tumour resistance. It is crucial to note that these mechanisms can vary across different cancer types and even among individual patients. Additionally, cancer cells can employ multiple mechanisms simultaneously or develop new resistance mechanisms over time, further complicating treatment strategies. Overcoming drug resistance remains a significant area of research, and ongoing efforts are focused on identifying and targeting these mechanisms in order to develop novel therapeutic strategies and enhance cancer treatment outcomes. This Special Issue will address subjects related to recent progress on mechanisms of drug resistance to targeted therapy in cancer therapy.

Guest Editors

Dr. Yan Li

School of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 1010, New Zealand

Dr. Johnson Liu

Department of Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia

Deadline for manuscript submissions

closed (25 November 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/175562

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)